- Home
- MOLN vs FULC Comparison
MOLN vs FULC Comparison
Compare MOLN & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- FULC
- Stock Information
- Founded
- MOLN 2004
- FULC 2015
- Country
- MOLN Switzerland
- FULC United States
- Employees
- MOLN N/A
- FULC N/A
- Industry
- MOLN
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- MOLN
- FULC Health Care
- Exchange
- MOLN Nasdaq
- FULC Nasdaq
- Market Cap
- MOLN 195.4M
- FULC 221.5M
- IPO Year
- MOLN 2021
- FULC 2019
- Fundamental
- Price
- MOLN $5.56
- FULC $3.96
- Analyst Decision
- MOLN
- FULC Hold
- Analyst Count
- MOLN 0
- FULC 10
- Target Price
- MOLN N/A
- FULC $7.44
- AVG Volume (30 Days)
- MOLN 7.1K
- FULC 1.0M
- Earning Date
- MOLN 03-13-2025
- FULC 02-25-2025
- Dividend Yield
- MOLN N/A
- FULC N/A
- EPS Growth
- MOLN N/A
- FULC N/A
- EPS
- MOLN N/A
- FULC N/A
- Revenue
- MOLN $7,105,397.00
- FULC $80,871,000.00
- Revenue This Year
- MOLN N/A
- FULC $2,821.96
- Revenue Next Year
- MOLN $29.41
- FULC N/A
- P/E Ratio
- MOLN N/A
- FULC N/A
- Revenue Growth
- MOLN N/A
- FULC 2987.86
- 52 Week Low
- MOLN $3.32
- FULC $2.86
- 52 Week High
- MOLN $12.70
- FULC $13.70
- Technical
- Relative Strength Index (RSI)
- MOLN 53.39
- FULC 41.64
- Support Level
- MOLN $4.98
- FULC $3.93
- Resistance Level
- MOLN $5.91
- FULC $5.17
- Average True Range (ATR)
- MOLN 0.27
- FULC 0.30
- MACD
- MOLN 0.08
- FULC -0.13
- Stochastic Oscillator
- MOLN 69.45
- FULC 3.97
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.